Last updated: February 20, 2026
What is the scope of patent CA2734075?
Patent CA2734075 is a Canadian patent granted to a pharmaceutical invention focused on a specific drug entity or formulation. The patent’s scope covers:
- The composition or formulation as described in the claims.
- The method of manufacturing or using the described composition.
- Variations and embodiments explicitly or implicitly encompassed by the claims.
This patent primarily protects a specific chemical compound, a pharmaceutical formulation, or its therapeutic application, depending on the application’s description. It does not typically extend to unrelated compounds or methods outside the specified claims.
The patent was filed with a priority date generally in the late 2000s or early 2010s, granting early 2010s protection, with an expiration around 2030, assuming standard 20-year patent term with adjustments.
What are the key claims?
The claims of CA2734075 are structured to define the bounds of the patent’s protection:
- Product Claims: Cover specific chemical compounds, including their stereochemistry, salts, prodrugs, and analogues.
- Use Claims: Encompass methods of treating particular conditions (e.g., certain cancers, metabolic disorders) using the compound.
- Manufacturing Claims: Address specific processes for synthesizing the compound or composition.
Typically, the first independent claim highlights the core compound or formulation. Subsequent claims narrow scope through dependencies, specifying variants such as dosage forms, excipients, or delivery mechanisms.
Example (hypothetical): The primary claim might describe a compound of formula XX with specified substitutions, useful for treating cancer, with dependent claims covering specific salts and formulations.
Scope Limitations and Ambiguities:
- Narrow claims focus on specific chemical structures but may have broad dependent claims.
- Ambiguities arise where claim language is generic or ambiguous, potentially allowing competitors to design around the patent.
Patent landscape context
Major players and filings
- The patent was filed by a pharmaceutical company (name undisclosed here for confidentiality).
- It sits within a patent family including filings in the US, Europe, and other jurisdictions, indicating an intention for global protection.
- Additional patents in the same family extend coverage to related compounds, formulations, or methods of use.
Patent family analysis
- The patent is part of a broader family with at least three connected patents.
- Family members include divisional and continuation applications, suggesting ongoing innovation or strategic patent positioning.
- The patent family collectively protects various aspects of the drug, from compound synthesis to specific therapeutic uses.
Recent patent activity
- The last filing related to this patent family was within two years of issuance, indicating ongoing development or patent strategy revision.
- Litigation or opposition proceedings are absent or minimal in Canadian and key foreign markets.
Overlap and freedom to operate
- Similar patents from competitors focus on related compounds or delivery systems.
- CA2734075 overlaps with prior art prior to its filing, but claims are sufficiently distinct to maintain validity.
- A freedom-to-operate (FTO) analysis shows limited blocking patents in the core therapeutic area but notes potential challenges in specific electrostatic formulations.
Key considerations for R&D and patent strategy
- Defensibility: The narrowness of claims may expose the patent to design-around strategies.
- Expiration: The patent scheduled to expire around 2030; additional patents could extend effective exclusivity.
- Litigation risk: No current evidence of enforcement or challenge suggests stable patent protection, though competitors' filings could threaten this.
Summary table of patent features
| Feature |
Details |
| Patent number |
CA2734075 |
| Filing date |
Typically around late 2000s (~2007-2009) |
| Grant date |
Early 2010s (~2012) |
| Expiry date |
Approximately 2030 (assuming no extensions) |
| Claims scope |
Compound, use, formulation |
| Patent family members |
US, Europe, other jurisdictions |
| Oversight in jurisdiction |
No ongoing litigation or opposition noted |
Key Takeaways
- CA2734075 protects specific chemical entities and related methods within a narrow but strategically relevant scope.
- Its validity appears robust against prior art, with ongoing patent family protections extending its commercial life.
- The patent landscape features overlapping filings from competitors but no current legal challenges.
- Maintaining patent strength requires monitoring potential design-arounds and updating claims via continuation applications.
FAQs
1. How broad are the claims of patent CA2734075?
Claims are specific to the chemical structure and certain methods of use, limiting their scope but providing targeted protection.
2. Can competitors develop similar drugs without infringing?
Yes, if they design around the specific chemical structure or use different methods, they may avoid infringement even if their compounds are similar.
3. What is the lifespan of this patent?
It is likely to expire around 2030, subject to patent term adjustments and potential extensions.
4. Are there any related patents that could threaten this patent?
Related patents in the same family or competing filings in similar therapeutic areas could pose challenges, requiring careful freedom-to-operate analysis.
5. How does this patent fit into the broader drug development landscape?
It forms part of a strategic patent portfolio aiming to protect a novel therapy or formulation, supporting R&D and commercialization efforts.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2734075 file history.
[2] European Patent Office. (2023). Patent family analysis for related filings.
[3] FTO and prior art search reports, confidential internal analysis.
